JERUSALEM, April 22, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com), a developer of oral delivery systems, announced today that the Company's CEO Nadav Kidron has been invited to be a panelist for a breakouts session at the BIO International Convention in Chicago, Illinois, USA. The breakout session, titled "Can Israel Become the Next Biotech Start-Up Nation?" will take place on Tuesday, April 23 rd, from 9:00-9:45am during the International Market Briefings Track.
In the last 20 years, Israel has become a model for high tech entrepreneurship. A country of 8 million people, Israel is home to a vibrant academic biomedical research sector, a global pharmaceutical company and several public biotech companies. Yet, the success of Israel's biotech sector pales in comparison to its high-tech industry. What can be learned from the Israeli Hi-tech Innovation and Entrepreneurship model and how can it be applied to biotech? What can Israel learn from other success models in biotechnology such as Massachusetts or California? Which regional partnerships can best leverage Israel's potential? What is the optimal positioning for Israeli Biotech to encourage biopharma companies and investors to step up their involvement?For more information on the panel please visit: http://mybio.zerista.com/event/member/64237 The BIO International Convention is hosted by the Biological Industry Organization (BIO) and is one of the largest and most widely attended annual conferences in the biotechnology sphere. For more information on BIO Chicago please visit: http://convention.bio.org/ About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem. For more information, the content of which is not part of this press release, please visit http://www.oramed.com . The company's fact sheet , the content of which is not part of this press release, can be viewed here . Forward-looking statements : This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. Company Contact: Oramed Pharmaceuticals Aviva Sherman Cell: +972-54-792-4438 Office: +972-2-566-0001 Email: firstname.lastname@example.org SOURCE Oramed Pharmaceuticals Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts